45 results
424B5
PRAX
Praxis Precision Medicines Inc
29 Mar 24
Prospectus supplement for primary offering
4:29pm
taxable disposition of our common stock or pre-funded warrants, which may be offset by U.S. source capital losses of the non-U.S. holder (even though
424B5
PRAX
Praxis Precision Medicines Inc
27 Mar 24
Prospectus supplement for primary offering
4:49pm
, which may be offset by U.S. source capital losses of the non-U.S. holder (even though the individual is not considered a resident of the United States
8-K
EX-99.1
PRAX
Praxis Precision Medicines Inc
5 Mar 24
Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results
7:13am
primarily reflects cash used in operations of $111.1 million during the year ended December 31, 2023, partially offset by $63.4 million in net proceeds from
424B5
y28gcqjoms bdx2ndsxv
12 Jan 24
Prospectus supplement for primary offering
5:20pm
424B5
ey37f0 sg9j132n
10 Jan 24
Prospectus supplement for primary offering
5:28pm
8-K
EX-99.1
nzrt2npb
7 Nov 23
Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2023 Financial Results
7:35am
8-K
EX-99.1
f7g3cyyb3vl28hr
9 Aug 23
Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2023 Financial Results
8:27am
424B5
z77jd 13s
20 Jun 23
Prospectus supplement for primary offering
6:02am
424B5
cgjwb67
15 Jun 23
Prospectus supplement for primary offering
5:26pm
8-K
EX-99.1
vhod4jgr00s88l4xp
9 Nov 22
Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2022 Financial Results
4:03pm